Allurion shrinks revenue, restates results and warns on going concern amid FDA PMA push

Company: Allurion Technologies, Inc. (NYSE: ALUR) - quick take: the business is shrinking top line, operating losses remain significant, management has restated prior-period results and disclosed material weaknesses, and the company is executing a major restructuring while pursuing FDA PMA completion for its Allurion Balloon.

What's happening inside the company
* Restatement / controls: Company restated prior quarters (including Q2‑2024) after identifying an error caused by material weaknesses in internal controls and insufficient public-company accounting experience.
* Governance / remediation: Management says disclosure controls were not effective as of 6/30/2025; hires and system changes are underway to remediate.
* Restructuring: November 2024 restructuring substantially completed in H1‑2025; additional strategic restructuring announced Aug 5, 2025 - reduction in force ~70 employees (~65% of workforce) and estimated severance ~$1.5M.
* Regulatory / product: AUDACITY pivotal trial topline posted; fourth/final PMA module submitted to FDA (July 2025). Sales in France were suspended in Aug 2024 but cleared to resume Feb 2025.
* Financing and covenant pressure: multiple equity offerings (Jul 2024, Jan & Feb 2025), RTW note facility and a Revenue Interest Financing (royalty-style obligation) create meaningful non‑equity claims on future revenue; recent conversion mechanics and amendments can dilute equity if triggered.

Key points & statistics (facts from the 10‑Q, all amounts in thousands unless noted)
* Revenue - Q2 2025: $3,379 vs Q2 2024 (restated) $11,766; 6M 2025: $8,959 vs 6M 2024: $21,152.
* Gross profit - Q2 2025: $2,497 vs Q2 2024: $8,993; 6M 2025: $6,658 vs 6M 2024: $15,859.
* Net loss - Q2 2025: $(9,335) vs Q2 2024 (restated): $(8,322); 6M 2025: $(10,836) vs 6M 2024: $(6,326).
* Net loss per share (basic & diluted) - Q2 2025: $(1.28); Q2 2024 (restated): $(4.34). Weighted‑average shares Q2 2025: 7,300,479 vs Q2 2024: 1,917,872.
* Cash & equivalents (6/30/2025): $12,722; Cash + restricted cash on cash flow statement: $13,064.
* Total assets (6/30/2025): $28,169; Total liabilities: $92,145; Stockholders' deficit: $(63,976).
* Significant liabilities (6/30/2025): Revenue Interest Financing liability $42,400; RTW Convertible Notes principal $46,520 (long‑term debt, net of change in fair value $28,770 on balance sheet); Warrant liabilities $7,200; Earn‑out liability $75.
* Cash flow - Net cash used in operations 6M 2025: $(17,082); financing proceeds during 6M 2025: $14,428 (public offerings, equity line); net decrease in cash 6M 2025: $(2,654).
* Going concern: management concluded there is substantial doubt about ability to continue as a going concern for one year from issuance date.

Positive aspects of the income statement / company position
* Gross margin remains positive: Q2 gross profit $2.497M on $3.379M revenue (shows product margin when units sell).
* Operating cost reduction: total operating expenses fell materially vs prior year periods as headcount and marketing were reduced (Sales & Marketing, R&D, G&A all declined vs prior-year periods).
* Progress on FDA pathway: AUDACITY results and submission of final PMA module are material de‑risking events for potential U.S. commercialization - if approved, could materially expand addressable market.
* Debt-to‑equity conversions and equity raises reduced some near-term cash service pressure (conversions in H1‑2025 converted some notes into ~1.49M shares on mandatory conversion action tied to market cap triggers).

Negative aspects of the income statement / company position
* Revenue collapse: Q2 revenue down ~71% year‑over‑year (11,766 → 3,379). Sales decline driven by distributor transitions, fewer direct sales, and market issues (France suspension at times).
* Significant and growing liabilities: Revenue Interest Financing $42.4M plus convertible note economics and warrant liabilities create heavy future claims on cash and/or equity dilution; fair‑value adjustments are volatile and have hurt reported results.
* Large recurring losses and cash burn: Operating loss and negative operating cash flow continue - $17.1M used in operations in H1‑2025; accumulated deficit $233.0M (6/30/2025).
* Material weaknesses & restatement: prior-period restatements, admission of ineffective disclosure controls, and accounting staff gaps raise credibility and execution risk for financial reporting.
* Going-concern and covenant risk: management states substantial doubt about ability to continue for one year without new financing - increases risk of dilutive financings or covenant-triggered conversions.
* High potential dilution and contingent issuances: multiple warrant tranches, earn‑outs (360k shares possible), convertible note conversion mechanics and Share Obligation could lead to heavy dilution if triggered.

Near-term catalysts and risks to watch (straightforward)
* FDA PMA decision / commercial pathway in U.S. - positive approval would be the largest upside catalyst; negative or delayed outcome is a material negative.
* Execution of restructuring and cost savings - whether the announced cuts and transition to distribution restore cash runway and improve margins.
* Cash runway / capital raises - monitor cash balance, operating burn, and whether the company secures non‑dilutive or less‑dilutive financing; failure likely forces more dilution or creditor remedies.
* RTW and revenue‑interest covenants - the financing imposes revenue royalties and minimums; shortfalls could accelerate cash obligations or conversions.
* Remediation of internal controls - investors should require a timeline and evidence of remediation to regain confidence in reported results.

Bottom line: Allurion (NYSE: ALUR) is a product‑stage medical device business with a promising FDA pathway but is trading operating‑loss reality for potential future upside. The company has cut costs and advanced the PMA, but revenue has fallen sharply, leverage and contingent liabilities are substantial, and internal control failures plus a going‑concern warning mean the stock carries high execution and financing risk. Watch FDA timing/results, cash runway, remediation progress, and any RTW conversion or royalty payments closely.